(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hexadecanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hexadecanoic acid
• 化学式: C35H52FNO5
• 分子量: 585.8
• InChiKey: VJTWHTROYJASAA-RVXRQPKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.88
• 重原子数：
  42
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  77
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PAROXETINE SALTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1102764A1

  公开（公告）日：2001-05-30
• [EN] PAROXETINE SALTS<br/>[FR] SELS DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000008016A1

  公开（公告）日：2000-02-17

  A salt of paroxetine with an acid selected from the group consisting of hydrobromic, hydroiodic, hexanoic, malic, aspartic, adipic, palmitic, stearic, ethylenediaminetetraacetic (EDTA), naphthoic, naphthalenesulphonic, pamoic, gluconic, salicylic, hydroxynaphthoic and hydroxybutyric acids, is useful in the treatment and prophylaxis of certain CNS disorders.
• [EN] A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY<br/>[FR] PROCÉDÉ POUR PRÉDIRE LA RÉPONSE D'UN PATIENT À UN TRAITEMENT PAR MODULATEURS DE SLC
  申请人：UNIV COLUMBIA

  公开号：WO2019046303A1

  公开（公告）日：2019-03-07

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.